For this Fool, the rise and fall of Valeant Pharmaceuticals International Inc (NYSE: VRX) is the most fascinating business story of 2015 -- and there are still a few chapters yet to be written. Below, ...

For a few weeks in January, Valeant Pharmaceuticals' (NYSE: VRX) stock outperformed the S&P 500 index. The run didn't last long, though. Here's why Valeant's rebound quickly fizzled. The first phase ...

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 SPY total return in the last five years is 131.9%. But there is no question some ...

The stock of Valeant Pharmaceuticals has crashed in recent days. A large factor in the crash was the use of GAAP earnings to justify a peak price of 10x sales and 105x earnings. Numerous companies in ...

(Reuters) - Valeant Pharmaceuticals Inc. sustained hits on several fronts on Thursday after CVS Health Corp and Express Scripts dropped Philidor from their networks in a sign the fallout from the ...

The Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock price has dropped 44% year to date and nearly 80% over the last three months.... The Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) stock price ...

Valeant's stock fell again even after filing its 10K. Comments from Berkshire's Buffett and Munger weighed on the stock. What Valeant Needs to Do to Restore Value. The annual filing did nothing to ...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) will report third-quarter fiscal 2016 earning results on Tuesday before the opening bell. And by the recent reaction in Valeant stock, investors are ...

Valeant will have to restate its earnings after it booked millions of dollars in sales at the wrong time. The pharmaceutical firm said in a statement late Monday that roughly $58 million in sales to ...